Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion

Biochemical Pharmacology

Volumn 80, Issue 7, 2010, Pages 1080-1086

  Hemauer, Sarah J ^a   Patrikeeva, Svetlana L ^a   Wang, Xiaoming ^a   Abdelrahman, Doaa R ^a   Hankins, Gary D V ^a   Ahmed, Mahmoud S ^a   Nanovskaya, Tatiana N ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Breast cancer resistance protein; Bupropion; P Glycoprotein; Placenta; Smoking

Indexed keywords

AMFEBUTAMONE; BREAST CANCER RESISTANCE PROTEIN; BUPROPION HYDROXIDE; DRUG METABOLITE; GLYCOPROTEIN P; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; VERAPAMIL; ANTIDEPRESSANT AGENT; CARRIER PROTEIN; MULTIDRUG RESISTANCE PROTEIN;

ACTIVE TRANSPORT; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN TISSUE; MEMBRANE VESICLE; MOLECULAR INTERACTION; PLACENTAL TRANSFER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; WESTERN BLOTTING; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PLACENTA; PREGNANCY; TRANSPORT AT THE CELLULAR LEVEL;

ANTIDEPRESSIVE AGENTS; BIOLOGICAL TRANSPORT; BUPROPION; FEMALE; HUMANS; MEMBRANE TRANSPORT PROTEINS; P-GLYCOPROTEIN; PLACENTA; PREGNANCY;

EID: 77955654070     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.06.025     Document Type: Article

References (31)

1. Rogers J.M. Tobacco and pregnancy. Reprod Toxicol 2009, 28(September (2)):152-160.
2. England L.J., Grauman A., Qian C., Wilkins D.G., Schisterman E.F., Yu K.F., et al. Misclassification of maternal smoking status and its effects on an epidemiologic study of pregnancy outcomes. Nicotine Tob Res 2007, 9(October (10)):1005-1013.
3. Lumley J., Oliver S.S., Chamberlain C.l. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2004, CD001055.
4. Slotkin T.A. If nicotine is a developmental neurotoxicant in animal studies dare we recommend nicotine replacement therapy in pregnant women adolescents?. Neurotoxicol Teratol 2008, 30:1-19.
5. Pauly J.R., Slotkin T.A. Maternal tobacco smoking nicotine replacement neurobehavioural development. Acta Paediatrica 2008, 97:1331-1337.
6. Xiao D., Huang X., Yang S., Zhang L. Direct effects of nicotine on contractility of the uterine artery in pregnancy. J Pharm Exper Ther 2007, 322:180-185.
7. Morales-Suarez-Varela M.M., Bille C., Christensen K., Olsen J. Smoking habits nicotine use congenital malformations. Obstet Gynecol 2006, 107:51-57.
8. Hurt R.D., Sachs D.P., Glover E.D., Offord K.P., Johnston J.A., Dale L.C., et al. A comparison of sustained-release bupropion placebo for smoking cessation. N Engl J Med 1997, 337:1195-1202.
9. ZYBAN® (bupropion hydrochloride) Sustained-Release Tablets Prescribing Information. The U.S. Food and Drug Administration website; 2010. Available at: [last accessed 14.04.2010]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020711s032s033lbl.pdf.
10. Earhart A.D., Patrikeeva S., Wang X., Reda Abdelrahman D., Hankins G.D., Ahmed M.S., et al. Transplacental transfer and metabolism of bupropion. J Matern Fetal Neonatal Med 2010, 23(May (5)):409-416.
11. Wang X., Abdelrahman D.R., Zharikova O.L., Patrikeeva S.L., Hankins G.D., Ahmed M.S., et al. Bupropion metabolism by human placenta. Biochem Pharmacol 2010, 79(June 1 (11)):1684-1690.
12. Sastry B.V.R., Owens L.K. Regional differential sensitivity of umbilico-placental vasculature to hydroxyltryptamine nicotine ethyl alcohol. Trophoblast Res 1987, 2:289-304.
13. Pastrakuljic A., Schwartz R., Simone C., Derewlany L.O., Knie B., Koren G. Transplacental transfer biotransformation studies of nicotine in the human placental cotyledon perfused in vitro. Life Sci 1998, 63:2333-2342.
14. Nekhayeva I.A., Nanovskaya T.N., Pentel P.R., Keyler D.E., Hankins G.D., Ahmed M.S. Effects of nicotine-specific antibodies Nic311 Nic-IgG on the transfer of nicotine across the human placenta. Biochem Pharmacol 2005, 70(November 25 (11)):1664-1672.
15. Hemauer S.J., Patrikeeva S.L., Nanovskaya T.N., Hankins G.D., Ahmed M.S. Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol 2010, 202(April (4)). 383.e1-7.
16. Wang J.S., Zhu H.J., Gibson B.B., Markowitz J.S., Donovan J.L., DeVane C.L. Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull 2008, 31(February (2)):231-234.
17. Bondarev M.L., Bondareva T.S., Young R., Glennon R.A. Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol 2003, 474(August 1 (1)):85-93.
18. Ushigome F., Koyabu N., Satoh S., Tsukimori K., Nakano H., Nakamura T., et al. Kinetic analysis of P-glycoprotein-mediated transport by using normal human placental brush-border membrane vesicles. Pharm Res 2003, 20(1):38-44.
19. Hemauer S.J., Patrikeeva S.L., Nanovskaya T.N., Hankins G.D., Ahmed M.S. Opiates inhibit paclitaxel uptake by P-glycoprotein in preparations of human placental inside-out vesicles. Pharm Res 2003, 20(1):38-44.
20. Awasthi S., Singhal S., Srivastava S.K., Zimniak P., Bajpai K.K., Saxena M., et al. Adenosine triphosphate-dependent transport of doxorubicin daunomycin vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. J Clin Invest 1994, 93(3):958-965.
21. Tsuruo T., Lida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41(5):1967-1972.
22. Benyahia B., Huguet S., Declèves X., Mokhtari K., Crinière E., Bernaudin J.F., et al. Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J Neuro Oncol 2004, 66(1-2):65-70.
23. Nanovskaya T.N., Deshmukh S., Brooks M., Ahmed M.S. Transplacental transfer metabolism of buprenorphine. J Pharmacol Exp Ther 2002, 300(1):26-33.
24. Miller R.K., Wier P.J., Zavislan J., Maulik D., Perez-D'Gregorio R., di Sant'Agnese P.A., et al. Human dual placental perfusions: criteria for toxicity evaluations. Methods Toxicol 1993, 205-245.
25. Hsyu P.H., Singh A., Giargiari T.D., Dunn J.A., Ascher J.A., Johnston J.A. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997, 37(August (8)):737-743.
26. Wang X., Meng M., Gao L., Liu T., Xu Q., Zeng S. Permeation of astilbin taxifolin in Caco-2 cell their effects on the P-gp. Int J Pharm 2009, 378(1-2):1-8.
27. Petsalo A., Turpeinen M., Tolonen A. Identification of bupropion urinary metabolites by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2007, 21(16):2547-2554.
28. Oncken C.A., Kranzler H.R. What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?. Nicotine Tob Res 2009, 11(November (11)):1265-1273.
29. Martin P., Massol J., Colin J.N., Lacomblez L., Puech A.J. Antidepressant profile of bupropion three metabolites in mice. Pharmacopsychiatry 1990, 23:187-194.
30. Sanchez C., Hyttel J. Comparison of the effects of antidepressants their metabolites on reuptake of biogenic amines on receptor binding. Cell Mol Neurobiol 1999, 19:467-489.
31. Talbot P. In vitro assessment of reproductive toxicity of tobacco smoke and its constituents. Birth Defects Res C Embryo Today 2008, 84(March (1)):61-72.